Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib-Reference-Cited by-同舟云学术

Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib

Published:2015-07-05 Issue:8 Volume:32 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Francis Jose,Dubashi Biswajit,Sundaram Rajan,Pradhan Suresh Chandra,Chandrasekaran Adithan

Funder

Science and Engineering Research Board (IN)

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-015-0665-0.pdf

Reference25 articles.

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7.

2. Lakshmaiah KC, Bhise R, Purohit S, et al. Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leuk Lymphoma. 2012;53:2430–3.

3. Deininger M, O’Brien S, Guilhot F, et al. International randomized study of interferon and STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Blood. 2009;114:Abstract 1126.

4. Gugliotta G, Castagnetti F, Palandri F, et al. Gruppo Italiano Malattie Ematologiche dell’Adulto CML Working Party. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood. 2011;117(21):5591–9.

5. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients;Drug Research;2023-01-11

2. BiCNN-CML: Hybrid Deep Learning Approach for Chronic Myeloid Leukemia;2022 5th International Conference on Contemporary Computing and Informatics (IC3I);2022-12-14

3. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?;Leukemia;2021-08-19

4. Medically Important Alterations in Transport Function and Trafficking of ABCG2;International Journal of Molecular Sciences;2021-03-10

5. ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?;Expert Opinion on Drug Metabolism & Toxicology;2021-02-02